Nuvectra (NVTR) Trading Down 5.4%

Shares of Nuvectra Corp (NASDAQ:NVTR) fell 5.4% during mid-day trading on Wednesday . The stock traded as low as $5.05 and last traded at $5.09. 506,936 shares were traded during mid-day trading, an increase of 110% from the average session volume of 241,960 shares. The stock had previously closed at $5.38.

Several research firms recently issued reports on NVTR. ValuEngine cut shares of Nuvectra from a “hold” rating to a “sell” rating in a report on Friday, May 3rd. JMP Securities cut their price target on shares of Nuvectra from $26.00 to $18.00 and set an “outperform” rating on the stock in a report on Thursday, May 2nd. They noted that the move was a valuation call. Raymond James cut their price target on shares of Nuvectra from $23.00 to $18.00 and set an “outperform” rating on the stock in a report on Friday, March 1st. Finally, BidaskClub cut shares of Nuvectra from a “hold” rating to a “sell” rating in a report on Tuesday, February 26th. Two analysts have rated the stock with a sell rating and five have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $20.40.

The firm has a market cap of $90.60 million, a PE ratio of -1.41 and a beta of -0.19. The company has a debt-to-equity ratio of 0.56, a quick ratio of 6.07 and a current ratio of 6.60.

Nuvectra (NASDAQ:NVTR) last posted its quarterly earnings results on Wednesday, May 1st. The company reported ($0.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.18). The company had revenue of $11.13 million during the quarter, compared to analyst estimates of $12.76 million. Nuvectra had a negative net margin of 98.77% and a negative return on equity of 62.18%. As a group, research analysts predict that Nuvectra Corp will post -3.03 EPS for the current fiscal year.

In other Nuvectra news, Director David D. Johnson bought 20,000 shares of the stock in a transaction on Monday, May 6th. The stock was purchased at an average price of $6.12 per share, for a total transaction of $122,400.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 2.90% of the stock is owned by insiders.

A number of hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. increased its stake in Nuvectra by 27.9% during the fourth quarter. BlackRock Inc. now owns 1,223,250 shares of the company’s stock valued at $19,989,000 after purchasing an additional 267,052 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in Nuvectra by 11.3% during the first quarter. Dimensional Fund Advisors LP now owns 764,043 shares of the company’s stock valued at $8,412,000 after purchasing an additional 77,413 shares during the last quarter. Cannell Capital LLC increased its stake in Nuvectra by 2,750.6% during the first quarter. Cannell Capital LLC now owns 723,349 shares of the company’s stock valued at $7,964,000 after purchasing an additional 697,974 shares during the last quarter. Vanguard Group Inc increased its stake in Nuvectra by 13.1% during the third quarter. Vanguard Group Inc now owns 677,798 shares of the company’s stock valued at $14,898,000 after purchasing an additional 78,724 shares during the last quarter. Finally, Vanguard Group Inc. increased its stake in Nuvectra by 13.1% during the third quarter. Vanguard Group Inc. now owns 677,798 shares of the company’s stock valued at $14,898,000 after purchasing an additional 78,724 shares during the last quarter. Hedge funds and other institutional investors own 82.58% of the company’s stock.

WARNING: This report was originally posted by Modern Readers and is owned by of Modern Readers. If you are reading this report on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The original version of this report can be viewed at https://www.modernreaders.com/news/2019/05/18/nuvectra-nvtr-trading-down-5-4.html.

Nuvectra Company Profile (NASDAQ:NVTR)

Nuvectra Corporation, a neurostimulation medical device company, develops and commercializes neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets. The company offers Algovita, a spinal cord stimulation system for the treatment of chronic intractable pain of the trunk and limbs.

Featured Article: What is Considered a Good Return on Equity (ROE)?

Receive News & Ratings for Nuvectra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra and related companies with MarketBeat.com's FREE daily email newsletter.